Kewaunee Scientific Corp Files Q2 2025 10-Q

TL;DR

KEQU Q2 2025 10-Q filed. Financials for period ending 10/31/24 are in.

AI Summary

Kewaunee Scientific Corp reported its Q2 2025 results for the period ending October 31, 2024. The company's financial performance for the first six months of fiscal year 2025, from May 1, 2024, to October 31, 2024, is detailed in this 10-Q filing. Specific revenue, net income, and balance sheet figures for this period are available within the document.

Why It Matters

This filing provides investors with the latest financial performance data for Kewaunee Scientific Corp, crucial for understanding the company's operational health and investment potential.

Risk Assessment

Risk Level: medium — The filing is a standard quarterly report, but the specific financial details within it could reveal underlying risks or strengths.

Key Numbers

• 20241031 — Period End Date (This is the end date for the reporting period covered by the 10-Q.)
• 20241213 — Filing Date (This is the date the report was officially filed with the SEC.)
• 0430 — Fiscal Year End (Indicates the end of Kewaunee Scientific Corp's fiscal year.)

Key Players & Entities

• KEWAUNEE SCIENTIFIC CORP /DE/ (company) — Filer
• 20241031 (date) — Conformed Period of Report
• 20241213 (date) — Filed as of Date
• 28677 (dollar_amount) — ZIP Code for Business Address
• 7048737202 (dollar_amount) — Business Phone Number

FAQ

Key Financial Figures

• $2.50 — ange on which registered Common Stock, $2.50 par value KEQU NASDAQ Global Market _

Filing Documents

• kequ-20241031.htm (10-Q) — 711KB
• certification311.htm (EX-31.1) — 4KB
• certification312.htm (EX-31.2) — 4KB
• certification321.htm (EX-32.1) — 3KB
• certification322.htm (EX-32.2) — 4KB
• certification311001.jpg (GRAPHIC) — 138KB
• certification312001.jpg (GRAPHIC) — 139KB
• certification321001.jpg (GRAPHIC) — 84KB
• certification322001.jpg (GRAPHIC) — 86KB
• 0000055529-24-000040.txt ( ) — 5392KB
• kequ-20241031.xsd (EX-101.SCH) — 41KB
• kequ-20241031_cal.xml (EX-101.CAL) — 73KB
• kequ-20241031_def.xml (EX-101.DEF) — 95KB
• kequ-20241031_lab.xml (EX-101.LAB) — 485KB
• kequ-20241031_pre.xml (EX-101.PRE) — 315KB
• kequ-20241031_htm.xml (XML) — 591KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements Condensed Consolidated Statements of Operations (unaudited) – Three and Six Months Ended October 31, 2024 and 2023 1 Condensed Consolidated Statements of Comprehensive Earnings (unaudited) – Three and Six Months Ended October 31, 2024 and 2023 2 Condensed Consolidated Statements of Stockholders' Equity (unaudited) – Three and Six Months Ended October 31, 2024 and 2023 3 Condensed Consolidated Balance Sheets – October 31, 2024 (unaudited) and April 30, 2024 4 Condensed Consolidated Statements of Cash Flows (unaudited) – Six Months Ended October 31, 2024 and 2023 5 Notes to Condensed Consolidated Financial Statements (unaudited) 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 16 Item 4.

Controls and Procedures

Controls and Procedures 16

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1A.

Risk Factors

Risk Factors 18 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 19 Item 5. Other Information 19 Item 6. Exhibits 19

SIGNATURES

SIGNATURES 20 i Part 1. Financial Information

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements Kewaunee Scientific Corporation Condensed Consolidated Statements of Operations (Unaudited) ($ and shares in thousands, except per share amounts) Three Months Ended October 31, Six Months Ended October 31, 2024 2023 2024 2023 Net sales $ 47,764 $ 50,436 $ 96,157 $ 100,275 Cost of products sold 33,812 36,968 69,717 74,893 Gross profit 13,952 13,468 26,440 25,382 Operating expenses 9,518 8,359 19,431 16,465 Operating profit 4,434 5,109 7,009 8,917 Pension expense — ( 40 ) — ( 81 ) Other (expense) income, net ( 61 ) 148 266 223 Interest expense ( 442 ) ( 372 ) ( 914 ) ( 802 ) Profit before income taxes 3,931 4,845 6,361 8,257 Income tax expense 916 2,015 1,108 2,912 Net earnings 3,015 2,830 5,253 5,345 Less: Net earnings attributable to the non-controlling interest 7 98 52 139 Net earnings attributable to Kewaunee Scientific Corporation $ 3,008 $ 2,732 $ 5,201 $ 5,206 Net earnings per share attributable to Kewaunee Scientific Corporation stockholders Basic $ 1.05 $ 0.94 $ 1.82 $ 1.81 Diluted $ 1.01 $ 0.93 $ 1.75 $ 1.79 Weighted average number of common shares outstanding Basic 2,872 2,903 2,861 2,882 Diluted 2,974 2,931 2,971 2,908 See accompanying notes to Condensed Consolidated Financial Statements. 1 Kewaunee Scientific Corporation Condensed Consolidated Statements of Comprehensive Earnings (Unaudited) ($ in thousands) Three Months Ended October 31, Six Months Ended October 31, 2024 2023 2024 2023 Net earnings $ 3,015 $ 2,830 $ 5,253 $ 5,345 Other comprehensive loss, net of tax: Foreign currency translation adjustments ( 76 ) ( 251 ) ( 192 ) ( 395 ) Other comprehensive loss ( 76 ) ( 251 ) ( 192 ) ( 395 ) Comprehensive earnings, net of tax 2,939 2,579 5,061 4,950 Less: Comprehensive income attributable to the non-controlling interest 7 98 52 139 Comprehensive earnings attributable to Kewaunee Scientific Corporation $ 2,932 $ 2,481 $ 5,009 $ 4,811 See accompanying

View Full Filing

View this 10-Q filing on SEC EDGAR